Elisha Finney Sells 378 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director Elisha Finney sold 378 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total transaction of $68,977.44. Following the completion of the sale, the director directly owned 4,871 shares of the company’s stock, valued at $888,860.08. This represents a 7.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

ICU Medical Trading Down 1.5%

Shares of NASDAQ:ICUI opened at $179.34 on Thursday. The business’s 50 day simple moving average is $154.67 and its 200 day simple moving average is $141.46. The company has a market capitalization of $4.48 billion, a P/E ratio of 151.98, a P/E/G ratio of 2.54 and a beta of 0.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical, Inc. has a 1 year low of $110.50 and a 1 year high of $192.85.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.ICU Medical’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. On average, research analysts anticipate that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ICUI shares. Zacks Research downgraded shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Needham & Company LLC lifted their target price on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and an average price target of $192.80.

Key Headlines Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Strong earnings and margin expansion support the investment case. ICU Medical’s latest quarterly results exceeded expectations, with EPS of $2.37 versus the $1.91 consensus and revenue of $547.88 million versus estimates of $533.44 million. A recent analysis also highlighted margin expansion and strength in the company’s infusion systems business. ICUI Q2 Deep Dive: Margin Expansion and Infusion Systems Drive Outperformance
• Positive Sentiment: Analysts raised price targets following the results. Needham lifted its target to $187, BTIG raised its target to $200, and Piper Sandler increased its target to $195 while maintaining an overweight rating. The consensus rating remains “Moderate Buy,” with an average price target of $192.80.
• Neutral Sentiment: Institutional ownership remains high. Several smaller investment firms recently initiated or increased positions in ICU Medical, while institutional investors and hedge funds collectively own approximately 96.1% of the shares. The reported short-interest data showed zero shares short, offering little indication of short-selling pressure.
• Negative Sentiment: Multiple insiders sold shares near recent highs. COO Christian B. Voigtlander sold 8,929 shares for approximately $1.63 million, CIO Ben Sousa sold 2,250 shares for about $401,000, and Director Elisha Finney sold 378 shares for roughly $69,000. The sales reduced their respective holdings by approximately 19.3%, 42.3% and 7.2%, potentially raising investor concerns about insider conviction. Top ICU Medical Executive Makes a Notable Move With Company Stock

Hedge Funds Weigh In On ICU Medical

Several institutional investors have recently modified their holdings of the business. Emerald Investment Advisers LLC bought a new position in ICU Medical in the 2nd quarter valued at $3,711,000. William Blair Investment Management LLC purchased a new stake in shares of ICU Medical during the 2nd quarter valued at approximately $25,242,000. Ieq Capital LLC purchased a new stake in shares of ICU Medical during the second quarter worth $906,000. Allworth Financial LP bought a new position in ICU Medical in the 2nd quarter worth about $26,000. Finally, Madison Asset Management LLC purchased a new position in ICU Medical during the second quarter valued at approximately $2,652,000. 96.10% of the stock is owned by institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.